Glaucoma Treatments Links

Glaucoma Treatments Links

Couldn't open rss feed in /links/glaucoma_treatments_page_2.php
Treating Glaucoma with Marijuana: The Evidence, Risks, and Side ...

Glaucoma treatment

The Dry Eye Digest - Dry eye blog: Abstract: Preserved vs ...

University of Dayton - News - Glaucoma Treatment Breakthrough

Outcome Sciences to Study Effectiveness of Glaucoma Treatments

<< 1 2 3 >>

· Home · Glaucoma Open Angle Resources · Laser Engineered Net Shaping Links

· Glaucoma diagnosis · Eye disease glaucoma · Argon laser trabeculoplasty · Glaucoma information · Selective laser trabeculectomy · Selective laser trabeculoplasty problems · Glaucoma open angle · Glaucoma laser surgery risks · Small laser cutting machines · Glaucoma laser treatment · Canine glaucoma · Glaucoma history · Laser prostate · Surgical laser technologies · Narrow angle glaucoma

A Patient's Guide to Glaucoma
by Young H Kwon John H Fingert Emily C Greenlee
Our Price: $16.15
Used from: $16.15

Shields' Textbook of Glaucoma (Allingham, Shields' Textbook of Glaucoma)

Our Price: $151.20
Used from: $18.71

Glaucoma-Patient to Patient-A Coping Guide for You and Your Family
by Edith Marks
Our Price: $26.95
Used from: $19.21

Cataract; Glaucoma and Other Eye Disorders : Prevention and Cure with Proven Natural Methods
by Tobe; John H.
Used from: $1.98

Surgical Techniques in Ophthalmology Series: Glaucoma Surgery: Text with DVD
by Teresa C. Chen MD FACS
Our Price: $116.80
Used from: $106.60

SLT Secrets Recommended Products

Glaucoma Treatments News

ThromboGenics Presents Positive Pooled Results From The MIVI-TRUST Phase III Program

ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France...

ThromboGenics presents positive pooled results from the MIVI-TRUST phase III programme at EURETINA

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST phase III programme were presented at the EURETINA (European Society of Retina Specialists) Congress in Paris, France.

ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

SAN DIEGO----ACADIA Pharmaceuticals Inc. , a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following investor conferences: The Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 14, 2010, at 12:30 p.m.

Somaxon Pharmaceuticals Announces Commercial Availability Of Silenor

Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company, today announced that Silenor® (doxepin) now is commercially available by prescription in the United States.

ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmin's ...

LEUVEN, Belgium, September 6, 2010 /PRNewswire-FirstCall/ -- - Data Presented at EURETINA Highlight the Attractive Characteristics of this Novel Potential Treatment Option for Retinal Disorders ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that ...

Home · Sitemap